BRICKELL BIOTECH INC (BBI) Stock Price & Overview
NASDAQ:BBI • US10802T2042
Current stock price
The current stock price of BBI is 2.35 USD. Today BBI is up by 2.17%. In the past month the price decreased by -35.26%. In the past year, price decreased by -93.39%.
BBI Key Statistics
- Market Cap
- 6.234M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -20.70
- Dividend Yield
- N/A
BBI Stock Performance
BBI Stock Chart
BBI Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to BBI. When comparing the yearly performance of all stocks, BBI is a bad performer in the overall market: 99.11% of all stocks are doing better.
BBI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BBI. Both the profitability and financial health of BBI have multiple concerns.
BBI Earnings
BBI Forecast & Estimates
8 analysts have analysed BBI and the average price target is 18.19 USD. This implies a price increase of 674.04% is expected in the next year compared to the current price of 2.35.
For the next year, analysts expect an EPS growth of 70.65% and a revenue growth 1253.05% for BBI
BBI Groups
Sector & Classification
BBI Financial Highlights
Over the last trailing twelve months BBI reported a non-GAAP Earnings per Share(EPS) of -20.7. The EPS decreased by -1880.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -8325.47% | ||
| ROA | -191.83% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
BBI Ownership
BBI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.96 | 368.645B | ||
| AMGN | AMGEN INC | 15.29 | 187.715B | ||
| GILD | GILEAD SCIENCES INC | 15.71 | 173.485B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.75 | 112.351B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.1 | 79.706B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.36 | 44.214B | ||
| INSM | INSMED INC | N/A | 31.674B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 30.229B | ||
| NTRA | NATERA INC | N/A | 29.365B | ||
| BIIB | BIOGEN INC | 11.09 | 26.496B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.72 | 25.315B | ||
| MRNA | MODERNA INC | N/A | 21.519B | ||
| INCY | INCYTE CORP | 12.57 | 19.324B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BBI
Company Profile
Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 16 full-time employees. The Company’s pipeline combines several development-stage candidates and a cutting-edge platform with autoimmune and inflammatory disorders program for the treatment of primary axillary hyperhidrosis. Its products include Cialis, Taltz, Gemzar, Prozac, Cymbalta and Juvederm. Its lead development-stage program, BBI-02, is a Phase I ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated in various preclinical models, including atopic dermatitis and rheumatoid arthritis. BBI-10, the Company’s lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows to inhibit both wild-type STING and gain-of-function mutants.
Company Info
IPO: 1993-03-10
BRICKELL BIOTECH INC
5777 Central Ave Ste 102
Boulder COLORADO 80301 US
CEO: Robert B. Brown
Employees: 16
Phone: 17205054755.0
BRICKELL BIOTECH INC / BBI FAQ
Can you describe the business of BRICKELL BIOTECH INC?
Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 16 full-time employees. The Company’s pipeline combines several development-stage candidates and a cutting-edge platform with autoimmune and inflammatory disorders program for the treatment of primary axillary hyperhidrosis. Its products include Cialis, Taltz, Gemzar, Prozac, Cymbalta and Juvederm. Its lead development-stage program, BBI-02, is a Phase I ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated in various preclinical models, including atopic dermatitis and rheumatoid arthritis. BBI-10, the Company’s lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows to inhibit both wild-type STING and gain-of-function mutants.
What is the current price of BBI stock?
The current stock price of BBI is 2.35 USD. The price increased by 2.17% in the last trading session.
Does BRICKELL BIOTECH INC pay dividends?
BBI does not pay a dividend.
What is the ChartMill rating of BRICKELL BIOTECH INC stock?
BBI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does BRICKELL BIOTECH INC have?
BRICKELL BIOTECH INC (BBI) currently has 16 employees.
What is the market capitalization of BBI stock?
BRICKELL BIOTECH INC (BBI) has a market capitalization of 6.23M USD. This makes BBI a Nano Cap stock.